{"source":"kalshi","id":"KXANITOCABTAGENE-27","ticker":"KXANITOCABTAGENE-27","slug":"KXANITOCABTAGENE-27","title":"FDA decision: Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences (in 2026)","description":null,"image":null,"icon":null,"active":true,"closed":false,"start_date":"2026-06-17T21:30:00Z","end_date":"2027-01-08T15:00:00Z","closed_time":null,"volume":458.47,"volume_24hr":164.72,"volume_24h_change":null,"normalized_vol_24hr":8.605024337768555,"normalized_volume":10.662707328796387,"liquidity":null,"open_interest":44.29,"categories":["Finance"],"tags":[],"synthetic":false,"is_group":false,"group_key":null,"parent_event_id":null,"probability":null,"spread":null,"top_outcome":"a full approval or an accelerated approval","top_outcome_probability":0.79,"top_outcome_prob_24h_change":0.0,"top_outcome_volume_24h_change":0.0,"updated_at":"2026-07-01T23:33:52.122958Z","fetched_at":"2026-07-01T23:33:52.122958Z","added_at":"2026-06-17T21:41:01.549286Z","url":"https://kalshi.com/markets/kxanitocabtagene/fda-decision-anitocabtagene-autoleucel-anito-cel-by-gilead-sciences-in-2026/kxanitocabtagene-27","chart_24h":null,"markets":[{"source":"kalshi","id":"KXANITOCABTAGENE-27-Y","event_id":"KXANITOCABTAGENE-27","slug":"KXANITOCABTAGENE-27-Y","question":"What will the FDA's decision be on Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences in 2026?","group_item_title":"a full approval or an accelerated approval","description":"If the FDA's decision on Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences in 2026 is a full approval or an accelerated approval, the market resolves to Yes.\n\n---\n\nThis market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued. \n\nAnitocabtagene autoleucel (anito-cel) is a personalized, one-time cell therapy made from a patient's own immune cells, reprogrammed in a laboratory to hunt and destroy cancer cells — think of it as taking a soldier from the patient's own army, giving it a custom-made targeting scope, and sending it back in. It is classified as a CAR-T (chimeric antigen receptor T-cell) therapy developed by Arcellx and commercialized in partnership with Gilead Sciences, designed to treat a blood cancer called multiple myeloma. In the trials studied here, it showed very high response rates, with nearly all treated patients responding to the therapy.","image":null,"icon":null,"outcomes":["Yes","No"],"outcome_prices":[0.79,0.20999999999999996],"probability":0.79,"spread":0.050000000000000044,"active":true,"closed":false,"start_date":"2026-06-17T21:30:00Z","end_date":"2027-01-08T15:00:00Z","closed_time":"2027-01-01T04:59:00Z","volume":458.47,"volume_24hr":164.72,"prob_24h_change":0.0,"volume_24h_change":0.0,"normalized_vol_24hr":9.221957206726074,"normalized_volume":11.113855361938477,"liquidity":null,"categories":["Finance"],"countries":["United States"],"updated_at":"2026-07-02T20:38:18.942735Z","fetched_at":"2026-07-02T20:38:18.942735Z","added_at":"2026-06-17T21:41:01.753016Z","url":"https://kalshi.com/markets/kxanitocabtagene/fda-decision-anitocabtagene-autoleucel-anito-cel-by-gilead-sciences-in-2026/kxanitocabtagene-27","event_title":"FDA decision: Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences (in 2026)","chart_24h":[0.79,0.79,0.79,0.79,0.79,0.79,0.79,0.79,0.79]}],"_meta":{"attribution":"pdata.world — aggregated prediction-market data across 8 platforms","canonical_url":"https://pdata.world/events/kalshi/KXANITOCABTAGENE-27","as_of":"2026-07-02T23:13:59.148962Z","docs":"https://api.pdata.world/docs","cite_as":"According to pdata.world (tracking Kalshi): \"FDA decision: Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences (in 2026)\" — top market at 79% probability across 1 outcome","source_url":null}}